全文获取类型
收费全文 | 2383篇 |
免费 | 124篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 39篇 |
儿科学 | 119篇 |
妇产科学 | 62篇 |
基础医学 | 308篇 |
口腔科学 | 26篇 |
临床医学 | 172篇 |
内科学 | 555篇 |
皮肤病学 | 48篇 |
神经病学 | 129篇 |
特种医学 | 53篇 |
外科学 | 217篇 |
综合类 | 46篇 |
预防医学 | 147篇 |
眼科学 | 97篇 |
药学 | 289篇 |
中国医学 | 17篇 |
肿瘤学 | 192篇 |
出版年
2023年 | 30篇 |
2022年 | 60篇 |
2021年 | 105篇 |
2020年 | 67篇 |
2019年 | 69篇 |
2018年 | 96篇 |
2017年 | 66篇 |
2016年 | 79篇 |
2015年 | 73篇 |
2014年 | 119篇 |
2013年 | 137篇 |
2012年 | 204篇 |
2011年 | 186篇 |
2010年 | 95篇 |
2009年 | 69篇 |
2008年 | 138篇 |
2007年 | 140篇 |
2006年 | 123篇 |
2005年 | 102篇 |
2004年 | 89篇 |
2003年 | 74篇 |
2002年 | 81篇 |
2001年 | 30篇 |
2000年 | 34篇 |
1999年 | 53篇 |
1998年 | 17篇 |
1997年 | 13篇 |
1996年 | 11篇 |
1995年 | 4篇 |
1994年 | 6篇 |
1993年 | 4篇 |
1992年 | 23篇 |
1991年 | 18篇 |
1990年 | 21篇 |
1989年 | 12篇 |
1988年 | 9篇 |
1987年 | 4篇 |
1986年 | 5篇 |
1985年 | 4篇 |
1984年 | 5篇 |
1982年 | 4篇 |
1981年 | 3篇 |
1980年 | 4篇 |
1977年 | 2篇 |
1975年 | 2篇 |
1974年 | 6篇 |
1972年 | 6篇 |
1970年 | 2篇 |
1969年 | 2篇 |
1968年 | 2篇 |
排序方式: 共有2516条查询结果,搜索用时 0 毫秒
61.
62.
63.
Evan J. Lipson Fizza F. Naqvi Manisha J. Loss Megan D. Schollenberger Drew M. Pardoll Jack Moore Daniel C. Brennan 《American journal of transplantation》2020,20(8):2264-2268
In this report, we describe the first kidney retransplantation performed after anti–programmed cell death‐1 (PD‐1)–related allograft rejection. In 2014, we administered pembrolizumab (anti–PD‐1) for ~9 months to a 57‐year‐old kidney transplant recipient with metastatic cutaneous squamous cell carcinoma (CSCC). The patient experienced both a complete antitumor response and T cell–mediated allograft rejection requiring reinitiation of hemodialysis. Four‐and‐a‐half years after initiating pembrolizumab, the patient remained without evidence of CSCC relapse and received a kidney transplant from a living‐unrelated donor. Ten‐and‐a‐half months after kidney retransplantation, the allograft is functioning well and the patient's CSCC remains in remission. This case illustrates the potential for PD‐1 blockade to bring about durable immune‐mediated tumor control in chronically immunosuppressed patients, and begins to address the feasibility of kidney retransplantation in patients who have previously received immune checkpoint inhibitor therapy for cancer. Results from this and future cases may help elucidate mechanisms of antitumor immunity and allograft tolerance, and inform updates to transplant decision models. Our report also underscores the need for clinical trials testing novel immunotherapy combinations in solid organ transplant recipients designed to uncouple antitumor and anti‐allograft immunity. 相似文献
64.
Manisha Choudhury 《Medicinal chemistry research》2014,23(6):3200-3206
Most metastatic cancer cells show a metabolic switch from normal oxidative phosphorylation to an increased rate of glycolysis named as the “Warburg effect.” Thus, even under hypoxic environments, Warburg effect provides a sufficient supply of energy from glucose. Isoform 5 of human lactate dehydrogenase (hLDH5) catalyzes the final step in the glycolysis (pyruvate to lactate) and constitutes a new anticancer target. In silico methods were employed to study the inhibitory property of the N-Hydroxyindole-based compounds against hLDH5. The compound ligands are subjected to Standard Precision (SP) docking and Extra Precision (XP) docking in GLIDE against the target protein hLDH5 [PDB ID: 1I10] each at the active site and at the cofactor binding site. Based on the docking score, glide energy, and hydrogen bonding interactions, six best compounds are selected and further subjected to Induced Fit Docking. Absorption, distribution, metabolism, and excretion (ADME) properties of the ligands are analyzed using QikProp. All computational methods are performed using Schrödinger suite 2009 USA. Compound 3m (6-[4-(2-carboxyethyl)phenyl]-1-hydroxy-1H-indole-2-carboxylic acid) showed the best conformational fit compared to the reference inhibitors. 相似文献
65.
66.
67.
Balakrishnan V Unnikrishnan AG Thomas V Choudhuri G Veeraraju P Singh SP Garg P Pai CG Devi RN Bhasin D Jayanthi V Premalatha N Chacko A Kar P Rai RR Rajan R Subhalal N Mehta R Mishra SP Dwivedi M Vinayakumar KR Jain AK Biswas K Mathai S Varghese J Ramesh H Alexander T Philip J Raj VV Vinodkumar A Mukevar S Sawant P Nair P Kumar H Sudhindran S Dhar P Sudheer OV Sundaram KR Tantri BV Singh D Nath TR 《JOP : Journal of the pancreas》2008,9(5):593-600
68.
69.
Nishant Tageja Elisabet E. Manasanch Neha Korde Mary Kwok Sham Mailankody Manisha Bhutani Mark Roschewski Ola Landgren 《European journal of haematology》2014,92(1):1-12
Since smoldering multiple myeloma (SMM) was first described over three decades ago based on a case series of six patients, its definition and our understanding of the entity have evolved considerably. The risk of progression to symptomatic myeloma (MM) varies greatly among individuals diagnosed with myeloma precursor disease. Epidemiologic, molecular, flow cytometric and radiological techniques have demonstrated that this transformation to MM from precursor states is not sudden but rather a continuous overlapping series of events with evidence of end‐organ damage that could manifest in the earliest stages of disease. Contemporary antimyeloma therapies can yield rapid, deep, and durable responses with manageable toxicities, and molecular‐cell‐based measures are now available to rule out minimal residual disease. With this information, clinical studies with correlative measures can now be developed to test the fundamental hypothesis that intervention in early myeloma may provide a measurable clinical benefit to patients by either delaying progression or eradicating plasma cell clones. 相似文献
70.
Michele Baccarani Brian J. Druker Susan Branford Dong-Wook Kim Fabrizio Pane Lidia Mongay Manisha Mone Christine-Elke Ortmann Hagop M. Kantarjian Jerald P. Radich Timothy P. Hughes Jorge E. Cortes François Guilhot 《International journal of hematology》2014,99(5):616-624
The TOPS trial evaluated high- (800 mg/day; n = 319) versus standard-dose (400 mg/day; n = 157) imatinib in patients newly diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Patients had a minimum follow-up of 42 months or discontinued early. Major molecular response (MMR) rates were similar between arms at (51.6 vs 50.2 % for 400 and 800 mg/day, respectively; P = 0.77) and by (75.8 vs 79.0 %; P = 0.4807) 42 months. There were no differences in event-free survival (EFS), progression-free survival (PFS), or overall survival (OS) between arms. The estimated rates of PFS on treatment and OS at 42 months were significantly higher in patients with MMR at 6, 12, and 18 months compared with those without MMR. Adverse events were more frequent with high-dose imatinib. Patients with ≤1 treatment interruption (vs >1) and those able to maintain imatinib ≥600 mg/day (vs <600 mg/day) in the first year of treatment had faster and higher response rates, but no improvement in EFS or PFS. Adherence to prescribed dose without interruption may be more important than initiation of therapy with higher doses of imatinib. Achievement of MMR correlated with long-term clinical outcomes. 相似文献